K
Kaiser Permanente | Division of Research
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
VX-121
VX-445
CTP-543
Icosapent Ethyl
pegcrisantaspase
BMS-986036
Aztreonam
Nucleos(t)Ide
Olaparib
Lenacapavir
Parent organization
This site is a part of Kaiser Permanente
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 23 total trials
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...
Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Olaparib 300mg tablets
The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.
Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: PTM F/TDF
Drug: Placebo SC LEN
Trial sponsors
S
S
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems